

ILS Laboratories

8222 Vickers St, Suite 106, San Diego, CA 92111
(619) 329-3999 | ils-lab.com

Cagrilintide 5mg + Semaglutide - 10mg

Tested for: Sequence Pure Peptides

www.SequencePure.com

COA #: COA-2026-58U7M_
Lot Number: SSP-070926
Accession #: ACC-2026-9458
Labeled Content: 10mg

Analysis Date: 07/16/2026
Appearance: Good
Sample Matrix: Lyophilized
Vial Size: 3mL
Date Received: 07/10/2026

PASS



Scan to verify
authenticity at ils-lab.com
Access Code: BE8KJ7GQ

Method: Blend Purity & Quant (HPLC)

Identity

Cagrilintide 5mg + Semaglutide

Peptide Purity

99.22%



Fentanyl
Free


Blend Purity & Quant (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	99.22%	%	PASS
Net Blend Peptide Content	Report Only	10.65	mg	N/A
-- Cagrilintide		5.34	mg	
-- Semaglutide		5.31	mg	
Identity (HPLC-RTM)	CAGRILINTIDE + SEMAGLUTIDE	Confirmed	-	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	-	PASS



Cagrilintide 5mg + Semaglutide 10mg
- SSP-070926

HPLC Chromatogram



Cagrilintide 5mg + Semaglutide 10mg - SSP-070926: UV Chromatogram

Notes & Methodology

- Date Tested: 07/16/2026. Methods: Blend Purity & Quant (HPLC).
- The sample was confirmed to be Cagrilintide 5mg + Semaglutide by HPLC. Identification by chromatographic retention time comparison with a reference standard.
- Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.
- Per-component content calculated from total net peptide content using the manufacturer's stated formulation ratio (Cagrilintide, Semaglutide). All components confirmed present by HPLC identity testing, unless explicitly stated otherwise.



Dr. Greg Kalyuzhny

Dr. Greg Kalyuzhny
Lab Director
7/16/2026

COA #: COA-2026-58U7M_
Access Code: BE8KJ7GQ
Verify: portal.ils-lab.com/verify/9YyKaloU2Ytw_vCK
Issued: 7/16/2026